구강질환 원인균에 대한 자몽종자추출물(GSE)과 법제유황수(PSS)의 항균활성을 확인하기 위해, 평판배지확산법 및 액체감수성실험법으로 Streptococcus mutans, Prevotella intermedia, Porphyromonas gingivalis 및 Candida albicans에 대한 항균활성을 측정하였다. 평판배지확산법의 경우, GSS의 농도가 40 ${mu}l$/disk일 때, S. mutans, P. intermedia, P. gingivalis 및 C. albicans에 대한 항균활성은 각각 11.0, 9.5, 8.0, 9.0 mm로 나타났으며, PSS의 농도가 40 ${mu}l$/disk일 때에는 각각 2.0, 3.5, 0.0, 1.5 mm로 나타났다. 또한 액체배지감수성실험에서 GSE에 대한 MIC 값은 0.24, 0.06, 0.10, 15.63 ${mu}l$/ml 이었으며, PSS 에 대한 MIC 값은 각각 0.12, 3.91, >125, 7.81 ${mu}l$/ml이었다. 치약 시제품의 항균효과를 확인하기 위해, GSE와 PSS가 농도별로 함유된 치약시제품 원액과 2배 및 4배 희석액을 제조하여 평판배지확산법을 수행한 결과, 0.5% 치약 시제품의 2배 희석액에서 각각 7.3, 4.3, 2.2 그리고 1.5 mm로 나타났다. 치약 시제품의 물리 화학적 특성을 확인한 결과, pH, 점도, 굴절 및 색도 변화에 있어서 모두 안정성을 보였고, 이상의 결과를 바탕으로 기능성 치약과 같은 구강질환 예방 및 치료제 개발 가능성을 확인하였다.
The aim of this study was to assess the effects of dentifrice-contatning grapefruit seed extract (GSE) and processed sulfur solution (PSS) on antimicrobial effects against oral pathogens. We first evaluated the antimicrobial effects of GSE and PSS against oral microbes: Streptococcus mutans (Sm), Prevotella intermedia (Pi), Porphyromonas gingivalis (Pg) and Candida albicans (Ca). When antimicrobial activity against Sm, Pi, Pg and Ca was tested, at 40 $mu$l/disk, the inhibition zones of GSE were 11.0, 9.5, 8.0 and 9.0 mm, respectively. With the same method, the inhibition zones of PSS were 2.0, 3.5, 0.0 and 1.5 mm, respectively. In the micro broth dilution method, the MIC values of GSE against Sm, Pi, Pg and Ca were 0.24, 0.06, 0.10 and 15.63 $mu$l/rnl, respectively. The MIC values of PSS were 0.12, 3.91,>125 and 7.81 $mu$l/ml, respectively. When pH, refractive index, viscosity and color value of dentifrice-containing GSE and PSS were measured, there were no significant changes in these physical properties compared to the control samples. Antimicrobial activities of dentifrice products containing 0.5% GSE and 0.5% PSS against oral pathogens were 7.3, 4.3, 2.2 and 1.5 mm, respectively. According to these results, we conclude that there may be a role for GSE and PSS in the development of new oral supplies.
